Diagnostics

Administration awards $600 million to bolster US manufacturing of COVID-19 tests and announces the re-opening of COVIDTests.gov

Sept. 21, 2023

Actions are part of ASPR’s comprehensive strategy to strengthen the domestic supply chain and promote access to COVID-19 tests.

LABline

The U.S. Department of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), is announcing an investment of $600 million across 12 domestic COVID-19 test manufacturers and the reopening of COVIDTests.gov to deliver COVID-19 tests for free to households across the country.

The awardees are:

$88.7 million for Access Bio in New Jersey.
$4.5 million for Advin in California.
$61.2 million for Azure in Texas.
$86.4 million for CorDx in California.
$167 million for iHealth in California.
$20.7 million for InBios in Washington.
$31.4 million for Kwell Laboratories in California.
$49.5 million for Maxim Bio in Maryland.
$5.7 million for OraSure Technologies in Pennsylvania.
$28.7 million for Princeton BioMeditech in New Jersey.
$28.6 million for Quidel in California.
$20.5 million for Sekisui in Delaware.

Combined, the 12 U.S. manufacturing companies operate production facilities across the country and employ hundreds of workers in seven states.

In addition to the investments in domestic manufacturing, beginning September 25, households will again be able to order four free tests through COVIDTests.gov. These tests will detect the currently circulating COVID-19 variants, are intended for use through the end of 2023, and will include clear instructions on how to verify extended expiration dates.

HHS release